Jiangsu Jibeier Pharmaceutical Co., Ltd. (SHA:688566)
China · Delayed Price · Currency is CNY 26.96
+0.57 (2.16%)
Aug 20, 2026, 3:00 PM CST
SHA:688566 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 5,422 | 5,953 | 4,467 | 5,935 | 4,004 | 4,266 | |
Market Cap Growth | -27.54% | 33.26% | -24.73% | 48.23% | -6.13% | -12.50% |
Enterprise Value | 4,672 | 5,098 | 3,515 | 5,188 | 2,916 | 3,022 |
Last Close Price | 26.96 | 29.55 | 21.82 | 29.90 | 20.28 | 21.05 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 21.24 | 22.76 | 20.37 | 27.09 | 25.89 | 37.13 |
Forward PE | - | 15.51 | 13.50 | 25.42 | 24.76 | - |
PS Ratio | 5.47 | 6.16 | 4.98 | 6.89 | 6.12 | 8.37 |
PB Ratio | 2.17 | 2.43 | 1.98 | 3.11 | 2.36 | 2.65 |
P/TBV Ratio | 2.27 | 2.55 | 2.04 | 3.21 | 2.46 | 2.77 |
P/FCF Ratio | 76.37 | 44.52 | 109.59 | - | - | 63.89 |
P/OCF Ratio | 29.73 | 23.98 | 20.75 | 37.21 | 26.57 | 28.34 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 4.72 | 5.28 | 3.92 | 6.03 | 4.45 | 5.93 |
EV/EBITDA Ratio | 17.80 | 19.07 | 11.61 | 21.47 | 17.72 | 25.33 |
EV/EBIT Ratio | 19.23 | 20.43 | 12.03 | 22.51 | 19.20 | 28.43 |
EV/FCF Ratio | 65.81 | 38.13 | 86.22 | - | - | 45.26 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.00 | 0.01 | 0.01 | 0.01 | - | - |
Debt / EBITDA Ratio | 0.01 | 0.07 | 0.07 | 0.04 | - | - |
Debt / FCF Ratio | 0.02 | 0.14 | 0.51 | - | - | - |
Net Debt / Equity Ratio | -0.31 | -0.34 | -0.39 | -0.38 | -0.59 | -0.76 |
Net Debt / EBITDA Ratio | -2.93 | -3.11 | -2.92 | -2.98 | -6.04 | -10.27 |
Net Debt / FCF Ratio | -10.83 | -6.21 | -21.65 | 3.64 | 7.00 | -18.35 |
Asset Turnover | 0.38 | 0.37 | 0.38 | 0.41 | 0.35 | 0.29 |
Inventory Turnover | 2.87 | 3.14 | 3.16 | 3.13 | 2.36 | 1.94 |
Quick Ratio | 8.73 | 6.88 | 6.86 | 5.23 | 6.67 | 11.06 |
Current Ratio | 9.35 | 7.09 | 7.04 | 5.38 | 6.93 | 11.33 |
Return on Equity (ROE) | 10.51% | 11.10% | 10.52% | 12.14% | 9.34% | 7.18% |
Return on Assets (ROA) | 5.76% | 5.95% | 7.71% | 6.90% | 5.02% | 3.73% |
Return on Invested Capital (ROIC) | 12.45% | 14.47% | 19.71% | 21.55% | 24.77% | 27.28% |
Return on Capital Employed (ROCE) | 9.40% | 9.80% | 12.50% | 11.50% | 8.50% | 6.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 4.69% | 4.40% | 4.91% | 3.69% | 3.86% | 2.69% |
FCF Yield | 1.31% | 2.25% | 0.91% | -3.33% | -3.55% | 1.57% |
Dividend Yield | 1.97% | 1.76% | 3.57% | - | 2.37% | 2.28% |
Payout Ratio | 40.82% | 39.64% | 46.94% | 20.48% | 58.02% | 78.09% |
Buyback Yield / Dilution | -1.74% | -2.89% | -3.65% | -0.49% | 1.07% | -11.81% |
Total Shareholder Return | 0.23% | -1.13% | -0.08% | -0.49% | 3.44% | -9.53% |